All In Biotech

Drug Trial Radar · NCT05933824

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LP-98 Injection in Healthy Subjects

A Randomized, Placebo-controlled, Single-administration, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LP-98 Injection in Healthy Subjects in a First-in-human Clinical Study

Last checked: Nov 19, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Actual

Start

Jul 13, 2023

Primary completion

Apr 12, 2024

Study completion Apr 12, 2024

Sponsor

Sponsor type
Industry
Collaborators
Institute of Pathogen Biology, Beijing, China
First posted
Jul 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A randomized, placebo-controlled, single-administration, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of LP-98 injection in healthy subjects in a first-in-human clinical study

Conditions

  • HIV (Human Immunodeficiency Virus)

Interventions

  • LP-98 injectionDrug

    Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes from baseline in respiration rate of Vital SignsTime frame: Within 36 days after the first administration.
  2. Changes from baseline in blood pressure of Vital Signs.Time frame: Within 36 days after the first administration.
  3. Changes from baseline in body temperature of Vital Signs.Time frame: Within 36 days after the first administration.
  4. Changes from baseline in ECG PR intervalThe cardiac rhythm is showed in 12 LeadsTime frame: within 36 days after administration
  5. Changes from baseline in ECG QRS intervalThe cardiac rhythm is showed in 12 LeadsTime frame: within 36 days after administration
  6. Changes from baseline in ECG QT intervalThe cardiac rhythm is showed in 12 LeadsTime frame: within 36 days after administration
  7. Changes from baseline in Blood lactate of Laboratory Examination.Time frame: within 36 days after administration
  8. Changes from baseline in Pregnancy test of Laboratory Examination.Time frame: within 36 days after administration
  9. Changes from baseline in red blood cell count of Laboratory Examination.Time frame: within 36 days after administration
  10. Changes from baseline in white blood cell count of Laboratory Examination.Time frame: within 36 days after administration
  11. Changes from baseline in neutrophil count of Laboratory Examination.Time frame: within 36 days after administration
  12. Changes from baseline in lymphocyte count of Laboratory Examination.Time frame: within 36 days after administration
  13. Changes from baseline in platelet count of Laboratory Examination.Time frame: within 36 days after administration
  14. Changes from baseline in hemoglobin of Laboratory Examination.Time frame: within 36 days after administration
  15. Changes from baseline in PT of Laboratory Examination.Time frame: within 36 days after administration
  16. Changes from baseline in INR of Laboratory Examination.Time frame: within 36 days after administration
  17. Changes from baseline in APTT of Laboratory Examination.Time frame: within 36 days after administration
  18. Changes from baseline in direct bilirubin of Laboratory Examination.Time frame: within 36 days after administration
  19. Changes from baseline in ALT of Laboratory Examination.Time frame: within 36 days after administration
  20. Changes from baseline in AST of Laboratory Examination.Time frame: within 36 days after administration
  21. Changes from baseline in total protein of Laboratory Examination.Time frame: within 36 days after administration
  22. Changes from baseline in albumin of Laboratory Examination.Time frame: within 36 days after administration
  23. Changes from baseline in creatinine of Laboratory Examination.Time frame: within 36 days after administration
  24. Changes from baseline in glucose of Laboratory ExaminationTime frame: within 36 days after administration
  25. Changes from baseline in potassium of Laboratory Examination.Time frame: within 36 days after administration
  26. Changes from baseline in sodium of Laboratory Examination.Time frame: within 36 days after administration
  27. Changes from baseline in chlorine of Laboratory Examination.Time frame: within 36 days after administration
  28. Changes from baseline in urine specific gravity of Laboratory Examination.Time frame: within 36 days after administration
  29. Changes from baseline in urine pH of Laboratory Examination.Time frame: within 36 days after administration
  30. Changes from baseline in urine glucose of Laboratory Examination.Time frame: within 36 days after administration
  31. Changes from baseline in urine protein of Laboratory Examination.Time frame: within 36 days after administration
  32. Changes from baseline in urine ketone body of Laboratory Examination.Time frame: within 36 days after administration
  33. Changes from baseline in urine white blood cell of Laboratory Examination.Time frame: within 36 days after administration
  34. Changes from baseline in urine occult blood of Laboratory Examination.Time frame: within 36 days after administration
  35. Changes from baseline in CK of Laboratory ExaminationTime frame: within 36 days after administration
  36. Changes from baseline in CK-MB of Laboratory ExaminationTime frame: within 36 days after administration
  37. Changes from baseline in LDH of Laboratory ExaminationTime frame: within 36 days after administration
  38. Changes from baseline in ALP of Laboratory ExaminationTime frame: within 36 days after administration
  39. Changes from baseline in Triglyceride of Laboratory ExaminationTime frame: within 36 days after administration
  40. Changes from baseline in CHOL of Laboratory ExaminationTime frame: within 36 days after administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Henan Provincial Hospital for Infectious Diseases (Zhengzhou Sixth People's Hospital)

    Zhengzhou, Henan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.